De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Sanofi is keep­ing an ear­ly pipeline of on­col­o­gy projects even as it axed clin­i­cal-stage pro­grams and re­al­lo­cat­ed re­sources to im­munol­o­gy, CEO Paul Hud­son told re­porters Thurs­day morn­ing.

Hud­son al­so said that the French phar­ma is not ex­pect­ing a sig­nif­i­cant im­pact from the US leg­is­la­tion tar­get­ing Chi­nese ser­vice providers giv­en the “grand­fa­ther na­ture” of ex­ist­ing re­la­tion­ships.

Sanofi, which is mak­ing moves to be an “im­munol­o­gy pow­er­house,” has made clear over the past few months that it’s look­ing to nar­row its on­col­o­gy work af­ter sev­er­al bold plat­form plays didn’t work out the way it had hoped. Those changes took shape in re­cent weeks with the planned di­vest­ment of Amu­nix, shut­ter­ing of Kiadis and shrink­ing of a deal with IGM. It’s al­so led to job cuts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER